Maintenance of statin use over 3 years following acute coronary syndromes: a national data linkage study (ANZACS-QI-2)

Heart. 2014 May;100(10):770-4. doi: 10.1136/heartjnl-2013-304960. Epub 2014 Jan 16.

Abstract

Objective: To describe patterns of statin use and predictors of poor maintenance over a 3-year period following an acute coronary syndrome (ACS).

Methods: National hospitalisation, mortality and pharmaceutical dispensing data were linked for all subjects aged 35-84 years discharged from a public hospital with an ACS in New Zealand in 2007. A Medication Possession Ratio (MPR; percentage of follow-up days patients were dispensed statins) was calculated for each patient. Adequate maintenance was defined by a MPR ≥80%.

Results: In 2007, 11 348 patients aged 35-84 years were discharged from hospital with ACS. Within 90 days of discharge, 83% had received a statin. Over the follow-up period, 66% were adequately maintained on a statin (MPR ≥80%): 69% in the first year, 67% in the second year and 66% in the third year. Patients taking statins prior to admission and those who underwent a coronary procedure were 20-50% more likely to have a MPR ≥80% over 3 years than others. In contrast, people aged 35-45 years and those of Maori or Pacific ethnicity were 13-25% less likely to have a MPR ≥80% than those aged 55-64 years and Europeans.

Conclusions: One-third of patients were not adequately maintained on statins over the 3-year period following ACS, but 82% of those on a statin prior to admission had an MPR ≥80% over 3 years of follow-up. These findings define achievable treatment levels and identify groups who may benefit from efforts to improve statin use.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Coronary Syndrome / drug therapy*
  • Acute Coronary Syndrome / mortality
  • Adult
  • Aged
  • Aged, 80 and over
  • Cause of Death / trends
  • Dose-Response Relationship, Drug
  • Female
  • Follow-Up Studies
  • Hospitalization / statistics & numerical data*
  • Hospitals, Public / statistics & numerical data
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
  • Male
  • Middle Aged
  • New Zealand / epidemiology
  • Prognosis
  • Retrospective Studies
  • Survival Rate / trends
  • Time Factors

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors